The Platform trial In COVID-19 priming and BOOsting (PICOBOO) is reported as a randomized controlled trial evaluating the immunogenicity, reactogenicity, and safety of seven licensed COVID-19 vaccines administered as a fifth dose or subsequent booster in immunocompetent adults. The article is published in Vaccine (2026 Aug 13;88:128970), DOI 10.1016/j.vaccine.2026.128970, and was made available online on 2026 Jul 28.
The PubMed entry identifies the work as a Vaccine article and as a randomized controlled trial. The citation metadata includes author names, institutional affiliations and a corresponding author electronic address (charlie.mcleod@health.wa.gov.au).
The stated focus of PICOBOO is to compare the immunogenicity, reactogenicity and safety profiles of seven licensed COVID-19 vaccines when delivered as a fifth dose or as subsequent booster doses in adults who are immunocompetent. The trial name explicitly indicates it is a platform trial addressing priming and boosting strategies for COVID-19 vaccination.
The PubMed content supplied confirms this objective and scope but does not include the study abstract or outcome data on the page excerpt provided here.
The PubMed listing classifies the work as a randomized controlled trial. Beyond that classification, the PubMed excerpt does not report trial-specific design details such as randomization procedures, allocation ratios, blinding, adaptive features characteristic of some platform trials, or sample size calculations. Those methodological details are not present in the supplied source content and therefore cannot be restated here.
The PubMed record lists numerous authors and institutional affiliations. The lead author is listed as C. McLeod with a corresponding electronic address. Contributing authors represent a range of Australian institutions, including but not limited to:
A UK contributor from the National Institute of Health Research / University Hospital Southampton and University of Southampton is also listed. The PubMed entry contains the full author list and affiliations but the supplied excerpt truncates some affiliation detail; the full record on PubMed or the journal full text should be consulted for the complete author and affiliation list.
The title and citation specify evaluation of seven licensed COVID-19 vaccines, delivered as a fifth dose or subsequent boosters. The PubMed excerpt does not list the specific vaccine product names, manufacturers, formulations (for example monovalent versus bivalent), doses, or administration routes. Those product-level details and any comparator arms are not reported in the provided PubMed content and therefore cannot be asserted here.
The article title and PubMed metadata make clear the trial population comprises immunocompetent adults receiving a fifth or later COVID-19 vaccine dose. The supplied source does not include detailed inclusion or exclusion criteria, age ranges, comorbidity specifications, prior infection or vaccine history requirements, or the total number of participants enrolled. Those participant-level specifics are not present in the PubMed excerpt.
The three primary domains assessed by the trial are stated in the title: immunogenicity, reactogenicity, and safety. However, the PubMed excerpt does not provide operational definitions for these endpoints (for example, antibody or cellular assays used, timing of immunogenicity measurements, solicited and unsolicited adverse events, severity grading, or safety monitoring procedures). Numeric results, comparative immunogenicity measures, reactogenicity rates, serious adverse event counts, and statistical analyses are not included in the provided source content.
Because the PubMed page content shown here omits the abstract and full results, no outcome data can be reported from this source alone.
The PubMed entry includes a link to full text options at Elsevier Science. The supplied PubMed excerpt does not include the study abstract or detailed methods and results sections. Accordingly, key elements required for clinical interpretation—specific vaccine names and formulations, sample size, randomization details, endpoint definitions, numerical immunogenicity outcomes, reactogenicity profile breakdowns, and safety event data—were not reported in the PubMed content provided for this rewrite.
For clinicians and researchers seeking numerical results, assay methods, subgroup analyses, and full methodological detail, consult the Elsevier full text linked from the PubMed record or access the journal issue (Vaccine, 2026;88:128970). The PubMed metadata and citation facilitate locating the complete article, but the PubMed excerpt itself does not contain the detailed trial data needed to summarize findings beyond the trial objective and publication metadata.
This rewritten summary and structured content are strictly limited to the information present in the supplied PubMed page excerpt. Where the PubMed content did not report specific methodological or outcome details, this document explicitly notes those omissions rather than inferring or inventing data. For complete trial results and actionable clinical interpretation, refer to the full-text article.